

# Eduardo Huarte

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1196377/publications.pdf>

Version: 2024-02-01

31  
papers

979  
citations

471509

17  
h-index

454955

30  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1455  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome. <i>Frontiers in Pharmacology</i> , 2021, 12, 650295.	3.5	23
2	Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models. <i>Immunotherapy</i> , 2021, 13, 977-987.	2.0	3
3	Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 6299-6309.	7.0	49
4	Probiotic-enriched milk and dairy products increase gut microbiota diversity: a comparative study. <i>Nutrition Research</i> , 2020, 82, 25-33.	2.9	32
5	Transgenic Tumor Models for Evaluating CAR T-Cell Immunotherapies. <i>Current Protocols in Pharmacology</i> , 2019, 86, e66.	4.0	0
6	Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2019, 134, 5608-5608.	1.4	1
7	Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy. <i>Blood</i> , 2019, 134, 1934-1934.	1.4	9
8	Gut microbiota metabolites for sweetening type I diabetes. <i>Cellular and Molecular Immunology</i> , 2018, 15, 92-95.	10.5	9
9	Regulatory T Cell Dysfunction Acquiesces to BTLA+ Regulatory B Cells Subsequent to Oral Intervention in Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2016, 196, 5036-5046.	0.8	16
10	Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 527-537.	2.5	10
11	Helper cell-independent antitumor activity of potent CD8+T cell epitope peptide vaccines is dependent upon CD40L. <i>Onc Immunology</i> , 2013, 2, e27009.	4.6	3
12	Gene Expression Profile of Peripheral Blood Lymphocytes from Renal Cell Carcinoma Patients Treated with IL-2, Interferon- $\gamma$ and Dendritic Cell Vaccine. <i>PLoS ONE</i> , 2012, 7, e50221.	2.5	17
13	Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE. <i>Journal of Autoimmunity</i> , 2011, 37, 328-341.	6.5	17
14	Active immunization using a single dose immunotherapeutic abates established EAE via IL-10 and regulatory T cells. <i>European Journal of Immunology</i> , 2011, 41, 313-323.	2.9	19
15	Apple polyphenols require T cells to ameliorate dextran sulfate sodium-induced colitis and dampen proinflammatory cytokine expression. <i>Journal of Leukocyte Biology</i> , 2011, 90, 1043-1054.	3.3	50
16	Murine and Bovine $\gamma\delta$ T Cells Enhance Innate Immunity against <i>Brucella abortus</i> Infections. <i>PLoS ONE</i> , 2011, 6, e21978.	2.5	51
17	Induction of Multi-epitopic and Long-Lasting Immune Responses Against Tumour Antigens by Immunization with Peptides, DNA and Recombinant Adenoviruses Expressing Minigenes. <i>Scandinavian Journal of Immunology</i> , 2009, 69, 80-89.	2.7	12
18	Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. <i>Cancer Letters</i> , 2009, 285, 80-88.	7.2	38

#	ARTICLE	IF	CITATIONS
19	Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity. <i>Cancer Research</i> , 2008, 68, 7684-7691.	0.9	105
20	PILAR is a novel modulator of human T-cell expansion. <i>Blood</i> , 2008, 112, 1259-1268.	1.4	37
21	The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN $\gamma$ . <i>International Journal of Cancer</i> , 2007, 121, 1282-1295.	5.1	16
22	Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma. <i>Cancer Research</i> , 2006, 66, 2442-2450.	0.9	129
23	Recombinant Adenoviral Vectors Turn on the Type I Interferon System without Inhibition of Transgene Expression and Viral Replication. <i>Molecular Therapy</i> , 2006, 14, 129-138.	8.2	38
24	Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. <i>International Journal of Cancer</i> , 2005, 116, 275-281.	5.1	112
25	Intratumoural administration of dendritic cells: hostile environment and help by gene therapy. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 7-22.	3.1	13
26	Carcinoembryonic Antigen as a Target to Induce Anti-Tumor Immune Responses. <i>Current Cancer Drug Targets</i> , 2004, 4, 443-454.	1.6	21
27	Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen. <i>International Journal of Cancer</i> , 2002, 97, 58-63.	5.1	11
28	Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements. <i>Clinical Cancer Research</i> , 2002, 8, 2336-44.	7.0	25
29	Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. <i>Clinical Cancer Research</i> , 2002, 8, 3219-25.	7.0	44
30	Characterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2 restricted cytotoxic T lymphocytes. <i>Journal of Hepatology</i> , 2001, 34, 321-329.	3.7	19
31	Specific and general HLA-DR binding motifs: comparison of algorithms. <i>Human Immunology</i> , 2000, 61, 266-278.	2.4	50